Peptide record

TPDB10815

Antibacterial Anticancer Hemolysis Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10815
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 26-aa standard-residue multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, HemoPI, and other sources, with an available 3D structural model.
Sequence
GLFGKLIKKFLRKAISYAVKKARGKH
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C140H237N41O29
NDCEQMPTW
K
2958.68
11.77
10
0
12
+9
1.31
-0.277
97.69
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
1490
0.50
2
Residue Composition
number
3
A
2
R
0
N
0
D
0
C
0
E
0
Q
3
G
1
H
2
I
3
L
7
K
0
M
2
F
0
P
1
S
0
T
0
W
1
Y
1
V
Amino Acid Distribution
A: 3 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 1 I: 2 L: 3 K: 7 M: 0 F: 2 P: 0 S: 1 T: 0 W: 0 Y: 1 V: 1
Chemical Descriptors
26 reviewed residue count
C140H237N41O29 sequence-only estimate (linear, free termini)
2958.68 sequence-only estimate (linear, free termini)
11.77 sequence-only estimate (linear, free termini)
+9 sequence-only estimate (linear, free termini)
1.31 sequence-only estimate (linear, free termini)
-0.277 sequence-only estimate (linear, free termini)
Evidence Records 4 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
3 µM
Hemolytic Cytotoxic
50% Hemolysis | 3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
N-terminal amphipathic helix as a trigger of hemolytic activity in antimicrobial peptides: a case study in latarcins. | FEBS Lett | 2009
Evidence 2 Activity

Activity

50% Cell death
Toxicity
3 µM
Cytotoxic
50% Cell death | 3 | µM | target cell: Human leukocytes

Target

Human leukocytes

Source & Reference

NA
DBAASP
N-terminal amphipathic helix as a trigger of hemolytic activity in antimicrobial peptides: a case study in latarcins. | FEBS Lett | 2009
Evidence 3 Activity

Activity

% Hemolysis
Toxicity
50 %
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 50% Hemolysis=3 µM | Cytotoxicity: Human leukocytes: 50% Cell death=3 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
FEBS Lett. 2009 Jul 21 583(14):2425-8.
Evidence 4 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis